Wako 和光纯药 011-27991 Anti Iba1, Goat Iba1抗体,山羊源多克隆抗体说明书

Wako 和光纯药 011-27991 Anti Iba1, Goat  Iba1抗体,山羊源多克隆抗体说明书

【Background】
Iba1 is a protein highly expressed in microglia and macrophages with a molecular weight of about 16.7 kDa1). The protein is a commonly known microglial marker in the nervous system.This item is a goat polyclonal antibody that reacts with Iba1.
For Research Use Only. Not for use in diagnostic procedures or therapeutic use.

小胶质细胞标记
Iba1是一种约17 kDa的蛋白,在神经系统小胶质细胞中特异性表达,经常被用作小胶质细胞标记物。 本产品是识别Iba1的山羊多克隆抗体。

【Description】

[Purification] Purified from the goat serum by antigen-affinity chromatography
[Reactivity] Reacts with Iba1
[Antigen] Synthetic peptide corresponding to the C-terminus of Iba1
[Clone No.] -( polyclonal)
[Species cross reactivity] Mouse and Rat(Other species have not been tested)
[Host] Goat
[Concentration] indicated on the label
[Formulation] TBS

[纯化]通过抗原亲和层析从山羊血清中纯化
[反应性]与Iba1反应
[抗原]对应于Iba1 C末端的合成肽
[克隆号]-(多克隆)
[物种交叉反应]小鼠和大鼠(尚未测试其他物种)
[主持人]山羊
标签上指示的[浓度]
[配方] TBS

【Applications】
Immunohistochemistry( frozen section) 1 : 250-1,000
Immunohistochemistry( paraffin section) 1 : 250-1,000
Western Blot 1 : 1,000
Optimal concentration should be determined by each laboratory
for each application.
【Storage】
Store at -20℃ .  Avoid repeated freeze and thaw.
【Package】
100μL
【Recommended protocol( Immunohistochemistry frozen section)】
Wistar rat or ICR mouse was perfusion-fixed with 4% paraformaldehyde.
replaced sucrose, and prepared 25μm brain section
by microtome.
Wash : 0.3% TritonX-100 in PBS, 5 min × 3

Blocking : 1% BSA and 0.3% TritonX-100 in PBS, 2 hour, RT

Primary antibody : goat anti-Iba1 (1/1000), 1% BSA, and 0.3%

TritonX-100 in PBS, overnight, 4℃

Wash : 0.3% TritonX-100 in PBS, 5 min × 3

Secondary antibody : AlexaFluor488 anti-goat IgG (1/1000,
Jackson Immuno Research Laboratories #705-545-147), 1%
BSA, and 0.3% TritonX-100 in PBS, 2 hour, RT

Wash : 0.3% TritonX-100 in PBS, 5 min × 3

Mount
【Reference】 参考文献
1) Imai, Y., Ibata, I., Ito, D., Ohsawa, K. and Kohsaka, S. : Biochem.
Biophys. Res. Commun., 224, 855( 1996).

◆应用实例 1:免疫组织染色(荧光染色)

Immunohistochemistry (fluorescent staining)

03700482_img04.png

数据提供:国立长寿医疗研究中心榊原老师

样品:阿尔茨海默病模型小鼠(APPNL-G-F 小鼠)大脑新皮层冰冻切片

一抗:抗Iba1,山羊多克隆抗体(1:1,000)

二抗:Alexa Fluor488标记抗山羊IgG

Aβ染色:0.001 % FSB溶液(淀粉样蛋白染色荧光探针)

数据提供:创价大学理工学部中嶋老师

样本:大鼠(左)以及小鼠(右)大脑皮质冰冻切片

一抗:抗Iba1,山羊多克隆抗体(1:250)

二抗:Alexa Fluor488标记抗山羊IgG

◆应用实例 2:免疫组织染色(DAB染色)

03700482_omg02.png

样品:小鼠脑额叶石蜡切片

一抗:抗Iba1,山羊(1:1,000)

二抗:抗山羊IgG,生物素标记

抗原激活:10 mM柠檬酸盐缓冲液(pH 6),90°C,处理10 min

◆应用实例3:蛋白印迹 Western Blotting

03700482_omg03.png

数据提供:创价大学理工学部中嶋老师

样品:大鼠原代培养小胶质细胞  10 μg

样品:大鼠原代培养神经元 10 μg

样品:大鼠原代培养星形胶质细胞  10 μg

样品:大鼠大脑皮层  100 μg

一抗:抗Iba1,山羊(1:1,000)

二抗:抗山羊IgG,HRP标记

抗原 合成肽(Iba1 C端序列相同)
储存缓冲液 TBS
亚型 山羊IgG
物种交叉性 大鼠、小鼠
抗体浓度 0.5-0.6 mg/mL
应用 免疫组化(冰冻切片)1:250-1,000
免疫组化(石蜡切片)1:250-1,000
免疫印迹 1:1,000

◆产品信息

产品编号 产品名称 规格 包装
011-27991 Anti Iba1, Goat

抗Iba1,山羊源多克隆抗体

免疫化学用 100 μL

◆相关产品

产品编号 产品名称 规格 包装
019-19741 Anti Iba1, Rabbit (for Immunocytochemistry)
小胶质细胞/巨噬细胞特异性蛋白抗体(免疫组化)
免疫化学用 50 μg
013-27691 Anti Iba1, Rabbit(for Paraffin Section)
小胶质细胞/巨噬细胞特异性蛋白兔源抗体(石蜡切片)
免疫化学用 50 μg
016-26461 Anti Iba1, Rabbit, Biotin-conjugated
小胶质细胞/巨噬细胞特异性蛋白抗体(结合生物素)
免疫化学用 100 μL
013-26471 Anti Iba1, Rabbit, Red Fluorochrome(635)-conjugated
小胶质细胞/巨噬细胞特异性蛋白抗体(结合红色荧光素635)
免疫化学用 100 μL
016-20001 Anti Iba1,Rabbit (for Western Blotting)
小胶质细胞/巨噬细胞特异性蛋白抗体(免疫印迹)
免疫化学用 50 μg
012-26723 Anti Iba1, Monoclonal Antibody(NCNP24)
抗Iba1,单克隆抗体(NCNP24)(鼠源)
免疫化学用 10 μL
017-27591 Anti Human Iba1, Monoclonal Antibody(NCNP27)
抗人 Iba1,单抗(NCNP27)
免疫化学用 10 μL

Wako 和光纯药 011-27991 Anti Iba1, Goat Iba1抗体,山羊源多克隆抗体

Wako 和光纯药 011-27991 Anti Iba1, Goat  Iba1抗体,山羊源多克隆抗体

名称:Anti Iba1, Goat
用途:for Immunochemistry

Storage Condition : Keep at -20 degrees C.

Application Data

Immunohistochemistry (fluorescent staining)

03700482_img04.png

Immunohistochemistry of frozen section in mouse model of Alzheimer’s disease (APPNL-G-F mouse) brain cerebral neocortex using anti Iba1, goat polyclonal antibody at dilution of 1:1,000, and anti goat IgG, Alexa Flour 488-conjugated. Aβ were stained by 0.001% FSB solution(Amyloid fluorescent probe). The data were provided by Dr. Sakakibara, National Center for Geriatrics and Gerontology in Japan.

 

Immunohistochemistry of frozen section in rat(left) and mouse(right) brain cerebral cortex using anti Iba1, goat polyclonal antibody at dilution of 1:250, and anti goat IgG, Alexa Flour 488-conjugated.
The data were provided by Dr. Nakajima from Soka University in Japan.

Immunohistochemistry(DAB staining)

03700482_omg02.png

Sample: paraffin section of mouse brain frontal lobe
1st antibody: Anti Iba1, goat(1:1.000)
2nd antibody: Anti goat IgG, biotin-conjugated
Antigen retrieval: 10mM citric acid buffer(pH6.0), 90℃, 10min

Western Blotting

03700482_omg03.png

The data were provided by Dr. Nakajima from Soka University in Japan.

Sample:
Microglia from rat primary culture 10μg
Neuron from rat primary culture 10μg
Astrocyte from rat primary culture 10μg
Cerebral cortex from rat brain 100μg

1st antibody: Anti Iba1, goat(1:1.000)
2nd antibody: Anti goat IgG, HRP-conjugated

Antibody Profile

Antigen Synthetic peptide corresponding to C-terminal of Iba1
Buffer TBS
Species cross-reactivity Rat and Mouse
Antibody concentration 0.5-0.7 mg/mL
Application Immunohistochemistry(frozen section) 1:250-1,000
Immunohistochemistry(paraffin section) 1:250-1,000
Western blotting 1:1,000

Overview / Applications

Outline Iba1 is a calcium-binding protein with a molecular weight of 17,000 specifically expressed in macrophage and microglia.This product is goat polyclonal antibody that specifically recognize Iba1, and is available for a microglial marker.

Antigen: synthetic peptide(C-terminal of Iba1)
Cross-reactivity: mouse, rat
Applications:
Immunohistochemistry(frozen section) 1:250-1,000
Immunohistochemistry(paraffin section) 1:250-1,000
Western Blotting 1:1,000

Property

Appearance Liquid

Alias

  • Anti Iba1, Goat Polyclonal Antibody
    Anti AIF1, Goat Polyclonal Antibody
    Anti IRT1, Goat Polyclonal Antibody

 

 

Wako 分散酶 Dispase CAS 9001-92-7

Wako 分散酶 Dispase CAS 9001-92-7

Dispase分散酶

Dispase分散酶是一类中性金属蛋白水解酶,可以回收生长在Matrigel基质上的细胞。与胰酶、胶原酶相比,它的作用更加温和,所以不会损伤细胞。此外,分散酶也可以用于组织分离。

来源:多粘芽孢杆菌表达的金属蛋白酶
使用指南:推荐浓度为10 U/cm2 BD Matrigel基质,如35 mm的培养皿推荐使用浓度为100U。
保存条件和效期:-20℃下冷冻保存,避免多次冻融。保质期详见产品包装。

Wako 分散酶 Dispase CAS 9001-92-7

383-02281 DISPASEⅡ 分散酶Ⅱ 1 g 9001-92-7
386-02271 DISPASE®Ⅰ 分散酶 10000 PU×6 9001-92-7

Roche公司的Dispase分散酶产品

货号 品名 规格
Roche-04942078001 Dispase® II (neutral protease, grade II) 1 g
Roche-04942078001 Dispase® II (neutral protease, grade II) 100mg

\

Wako和光纯药抑制剂 Inhibitor

Wako和光纯药抑制剂 Inhibitor

上海金畔生物代理Wako和光纯药全线产品,欢迎新老客户访问Wako和光纯药官网或者咨询我们获取更多相关产品信息。

Wako和光纯药代理

货号 品名 规格
307-50771 α-Amylase Inhibitor, From Wheat  α-淀粉酶抑制剂,来源于小麦 1MG
335-40623 Antipain 25MG
333-40624 Antipain 100MG
339-40621 Antipain 0.5MG
253-00471 YC-1 5MG
244-00721 Xestospongin C 100UG
210-00921 U-73343 5MG
213-00911 U-73122 5MG
211-01051 U0126 5MG
208-09223 Trypsin Inhibitor, from Soybean
胰蛋白酶抑制剂,大豆来源
1G
204-09225 Trypsin Inhibitor, from Soybean
胰蛋白酶抑制剂,大豆来源
5G
202-09226 Trypsin Inhibitor, from Soybean
胰蛋白酶抑制剂,大豆来源
500MG
202-09221 Trypsin Inhibitor, from Soybean
胰蛋白酶抑制剂,大豆来源
100MG
204-11991 Trichostatin A
曲古柳菌素A
5MG
200-11993 Trichostatin A
曲古柳菌素A
1MG
206-15471 Trichodion 100UG
209-14481 N-Tosyl-L-phenylalanine Chloromethyl Ketone(TPCK) 250MG
205-14483 N-Tosyl-L-phenylalanine Chloromethyl Ketone(TPCK) 1G
208-09181 (+/-)-alpha-Tocopherol Nicotinate
alpha-维生素E烟酸酯
5G
206-09182 (+/-)-alpha-Tocopherol Nicotinate
alpha-维生素E烟酸酯
25G
207-15641 TMP-153 500MG
164-17321 DL-threo-PPMP Hydrochloride
D,L-苏式-PPMP盐酸盐
25MG
161-17331 DL-threo-PPMP Hydrochloride
D,L-苏式-PPMP盐酸盐
50MG
206-10351 1-(2-Tetrahydrofuryl)-5-fluorouracil
1-(2-四氢呋喃基)-5-氟尿嘧啶
1G
202-10353 1-(2-Tetrahydrofuryl)-5-fluorouracil
1-(2-四氢呋喃基)-5-氟尿嘧啶
5G
209-12041 Tautomycin
泰托霉素
100UG
198-10281 Swainsonine
八倾吲嗪三醇
1MG
196-12703 Sulindac
舒林酸
50G
190-12701 Sulindac
舒林酸
10G
195-12491 Sulfuretin
硫黄菊素
20MG
333-31091 SUC-GLY-PRO-MCA 5MG
549-00286 STREPTOZOTOCIN 5G
543-00284 STREPTOZOTOCIN 1G
545-00283 STREPTOZOTOCIN 500MG
549-00281 STREPTOZOTOCIN 100MG
198-08515 Streptomycin Sulfate
硫酸链霉素
500G
192-08513 Streptomycin Sulfate
硫酸链霉素
100G
194-08512 Streptomycin Sulfate
硫酸链霉素
25G
196-08511 Streptomycin Sulfate
硫酸链霉素
5G
197-10251 Staurosporine
星形孢菌素
100UG
193-10253 Staurosporine
星形孢菌素
500UG
191-11533 Spectinomycin Dihydrochloride Pentahydrate
盐酸壮观霉素
1G
195-11531 Spectinomycin Dihydrochloride Pentahydrate
盐酸壮观霉素
5G
193-12051 Simvastatin
新伐他丁
25MG
194-13561 γ-Secretase Inhibitor X 1MG
188-01593 Roscovitine, 98.0+ % (HPLC)
细胞周期蛋白B激酶抑制剂
10MG
182-01591 Roscovitine, 98.0+ % (HPLC)
细胞周期蛋白B激酶抑制剂
1MG
181-01723 Resveratrol
白藜芦醇
500MG
185-01721 Resveratrol
白藜芦醇
100MG
183-01901 Radicicol
根赤壳菌素
1MG
165-20281 Protease Inhibitor Mixture-DMSO Solution for Fungal and Yeast Extracts 1ML
161-11493 Prednisolone
强的松龙
5G
165-11491 Prednisolone
强的松龙
1G
162-19821 Pravastatin Sodium Salt
普伐他汀
25MG
168-19823 Pravastatin Sodium Salt
普伐他汀
100MG
163-20341 PP-3
PP3酪氨酸激酶抑制剂
1MG
166-20331 PP 2, 94.0+ % (HPLC) 1MG
166-20294 Piroxicam
炎痛喜康
10G
162-20291 Piroxicam
炎痛喜康
1G
168-20293 Piroxicam
炎痛喜康
5G
160-17781 Phloretin, 98.0+ % (HPLC)
根皮素
250MG
160-11181 Pepsinostreptin
抑胃酶素
10MG
163-20101 PACOCF3
1,1,1-三氟-2-十七烷酮
10MG
144-07331 NS-398
COX-2选择性抑制剂NS-398
5MG
140-07333 NS-398
COX-2选择性抑制剂NS-398
25MG
147-07343 Niflumic Acid
尼氟酸
250G
141-07341 Niflumic Acid
尼氟酸
50G
145-06381 Nicardipine Hydrochloride, 99.0+ % (HPLC)
盐酸尼卡地平
1G
141-06383 Nicardipine Hydrochloride, 99.0+ % (HPLC)
盐酸尼卡地平
5G
145-06761 NF-κB inhibitor SN50 500UG
147-07201 (S)-(+)-Naproxen
(S)-(+)-萘普生
5G

Wako 074-06161 Glutelin, from Ric

Wako 074-06161 Glutelin, from Ric

Glutelin, from Rice(Yamadanishiki)
级别:for Cellbiology
代理商 : FUJIFILM Wako Pure Chemical Corporation
保存条件Storage Condition : Keep at 2-10 degrees C.

This product is for research use only. Do not administer it to human.

Glutelin is a major protein in rice, and defined as protein which dissolves in dilute acid and alkali.
In Japanese sake brewing, the byproducts of protein breakdown are considered to be a decisive factor in establishing flavor. The National Tax Agency of Japan has determined a special method to measure carboxypeptidase activity in koji mold (Aspergillus oryzae) used for fermentation. However, in recent years it has been reported that synthetic peptide substrates approved by this test are impractical in producing enzymatic activity from koji mold. To this extent, gluterin derived from rice has been shown to be an ideal solution to this problem.

Wako 014-18331 Acibenzolar-S-methyl Standard 噻二唑素-S-甲基标准品

Wako 014-18331 Acibenzolar-S-methyl Standard 噻二唑素-S-甲基标准品

英文名称:Acibenzolar-S-methyl Standard
中文名称:噻二唑素-S-甲基标准品
品牌:Wako
CAS No.:135158-54-2
储存条件:2-10℃(RT)
纯度:99.0+% (qNMR)

其他农残兽残分析相关产品:

施用于作物上的农药,其中一部分附着于作物上,一部分散落在土壤、大气和水等环境中,环境残存的农药中的一部分又会被植物吸收。残留农药直接通过植物果实或水、大气到达人、畜体内,或通过环境、食物链最终传递给人、畜。

到目前为止,世界上化学农药年产 量近200万吨,约有1000多种人工合成化合物被用作杀虫剂、杀菌剂、杀藻剂、除虫剂、落叶剂等类农药。农药尤其是有机农药大量施用,造成严重的农药污染问题,成为对人体健康的严重威胁。

农药残留对健康的影响

食用含有大量高毒、剧毒农药残留引起的食 物会导致人、 畜急性中毒事故。长期食用农 药残留超标的农副产品,虽然不会导致急性中 毒,但可能引起人和动物的慢性中毒,导致疾病的发生,甚至影响到下一代。

影响农业生产

由于不合理使用农药,特别是除草剂, 导致药害事故频繁, 经常 引起大面积减产甚至绝产,严重影响了农业生产。土壤中残留的长残 效除草剂是其中的一个重要原因。

影响进出口贸易

世 界各国,特别是发达国家对农药残留问题高度重视, 对各种农副产品 中农药残留都规定了越来越严格的限量标准。许多国家以农药残留限量为技术壁垒,限制 农副产品进口,保护农业生产。2000年,欧共体将氰戊菊酯在茶叶中的残留限量从 10毫克/千克降低到0.1毫克/千克,使中国茶叶出口面临严峻的挑战。

农残限量

世界卫生组织和联合国粮 农组织(WHO/FAO)对农药残留限量的定义为 , 按照良好的农业生产(GAP)规范,直接或间接使用农药后,在食品和饲料中形成的农药残留物的最大浓度。目前,中国已制定了79种农药在32种(类 )农副产品中197项农药最高残留限量 (MRL)的国家标准。

农药标准品 (一)

农残专用级别或HPLC级别的农药标准品, 纯度均大于98%。

产品编号 产品名称 中文名称 CAS NO. 包装
205-16281 beta-Trenbolone Standard 三烯酮标准品 10161-33-8 200mg
020-15311 Butylhydroxyanisole Standard (mixture of isomers) 丁基羟基茴香醚标准品 25013-16-5 200mg
086-08241 Hydrocortisone Standard 氢化可的松标准品 50-23-7 200mg
158-02531 Oxacillin Sodium Monohydrate Standard 苯唑西林钠一水合物标准品 7240-38-2 200mg
159-2561 Oxydozanide Standard 五氯柳胺标准品 2277-92-1 200mg
208-16271 Trenbolone Acetate Standard 乙酸去甲雄三烯醇酮标准品 10161-34-9 200mg
159-02681 (5Z)-Orysastrobin Standard (5z)-肟醚菌胺标准品   50mg
011-20051 (Aminomethyl)phosphonic Acid Standard 氨甲基磷酸标准品 1066-51-9 200mg
044-26063 (E)-Dimethylvinphos Standard E-甲基毒虫畏标准品 71363-52-5 50mg
063-04131 (E)-Ferimzone Standard E-嘧菌腙标准品   200mg
139-15891 (E)-Metominostrobin Standard (E)-苯氧菌胺标准品 133408-50-1 100mg
132-15521 (E)-Mevinphos Standard (E)-速灭磷标准品 298-01-1 100mg
167-16691 (E)-Pyrifenox Standard E-啶斑肟标准品 83227-22-9 200mg
166-19841 (E)-Pyriminobac-methyl Standard 嘧草醚标准品 147411-696 200mg
215-01331 (R)-Uniconazole Standard 烯效唑标准品 83657-16-3 50mg
023-12741 (RS)-s-Butylamine Standard (+/-)-1-甲基丙胺标准品 13952-84-6 200mg
045-25231 (Z)-DimethyMnphos Standard (Z)二甲基亚硝胺标准品 67628-93-7 200mg
067-05011 (Z)-Fenpyroximate Standard (z)-唑螨酯标准品 149054-53-5 20mg
066-04121 (Z)-Ferimzone Standard (Z)-嘧菌腙标准品 89269-64-7 200mg
139-15911 (Z)-Metominostrobin Standard (z)-苯氧菌胺标准品 133408-51-2 20mg
139-15531 (Z)-Mevinphos Standard (Z)-速灭磷标准品 33845-4 100mg
160-16701 (Z)-Pyrifenox Standard (Z)-比芬诺标准品 83227-23-0 200mg
163-19851 (Z)-Pyriminobac-methyl Standard (z)-嘧草醚标准品 147411-709 50mg
044-29601 1.1-DiChloro-2.2-bis(4-ethylphenyl)Ethane Standard l,1-二氯-2,2-二(4-乙苯)乙烷标准品 72-56-0 200mg
054-04121 1 2-DIbromoEthane Standard Solution l,2-二溴甲烷标准溶液 106-93-4 1mLx5
133-14831 1-Methylpiperidine Standard 1-甲基哌啶标准品 626-67-5 200mg
141-06501 1-Naphthylacetamide Standard 萘乙酰胺标准品 86-86-2 200mg
148-06511 1-Naphthylacetic Acid Standard a-萘乙酸标准品 86-87-3 200mg
208-11911 2,4,5-T Standard 2,4,5-T标准品 93-76-5 200mg
204-13451 2,4,5-T-butyl Standard 2,4,5-特丁基标准品 93-79-8 200mg
203-15481 2,4,6-Tnchlorophenol Standard 三氧苯酚标准品 32296 200mg
048-29741 2,4-DB Standard 2,4-DB标准品 94-82-6 200mg
045-25591 2,4-DiChloroaniline Standard 2,4-二氯苯胺标准品 554-00-7 200mg
164-18161 2,4-PA-butyl Standard 2,4-聚酰胺-丁基标准品 94-80-4 200mg
045-29371 2,6-Difluorobenzoic Acid Standard 2,6-二氟苯甲酸标准品 385-00-2 200mg
043-29811 2,6-Diisopropylnaphthalene Standard 2,6-二异丙基标准品 24157-81-1 200mg
011-08711 2-Aminobenzimidazole Standard 2-氨基苯并咪唑标准品 93432-7 200mg
169-17871 2-Phenylphenol Standard 邻苯基苯酚标准品 90-43-7 200mg
206-16951 3-(2,4,6-TrimethylphenylsuIfonyl)-1,2,4-triazole Standard 3-(2,4,6三甲基苯基磺酰基)-1,2,4三唑标准品 149591-20-8 S0mg
134-11941 3-(Methylphosphinico)propionic Acid Standard 3-(甲基膦酸基)丙酸标准品 15090-23-0 200mg
085-08571 3-Hydroxycarbofuran Standard 3-羟基呋喃丹标准品 16655-82-6 50mg
046-28441 4,4-Dimethyl-2-oxazolidinone Standard 4,4-双甲基-2-噁唑烷酮标准品 26654-39-7 200mg
030-19511 4-CPA Standard 对氧苯氧乙酸标准品 122-88-3 200mg
086-08501 4-Hydroxybiphenyl Standard 对羟基苯酚标准品 92-69-3 200mg
131-15731 4-Methyl-1,2,3 thiadiazole-5-Carboxylic Acid standard 4-甲基-1,2,3-噻二唑-5-甲酸标准品 18212-21-0 100mg
080-08521 5-Hydroxythiabendazole Standard 5-羟基噻苯咪唑标准品 948-71-0 20mg
022-15251 6-Benzylaminopunne Standard 6-苄氨基嘌呤标准品 1214-39-7 200mg
032-20561 6-Chloropicolinic Acid Standard 2-氯吡啶-6-羧酸标准品 4684-94-0 100mg
016-20361 Abamectin Standard 阿维菌素标准品 71751-41-2 200mg
018-18591 Acequinocyl Standard 灭螨醌标准品 57960_19_7 200mg
011-18601 Acequinocyl-hydroxy Standard 羟基灭螨醌标准品 57960-31-3 200mg
014-16491 Acetamiprid Standard 啶虫脒标准品 160430-64-8 200mg
013-20511 Acetochlor Standard 乙草胺标准品 34256-82-1 100mg
018-19451 Acibenzolar Acid Standard 阿拉酸式苯标准品 35272-27-6 100mg
014-18331 Acibenzolar-S-methyl Standard 阿拉酸式苯-S-甲基标准品 135158-542 200mg
010-20521 Aafluorfen Standard 三氟羚草醚标准品 50594-66-6 200mg
013-15741 ACN Standard ACN标准品 2797-51-5 200mg
018-16651 Acrinathrin Standard 氟丙菊酯标准品 101007-06-1 200mg
017-15521 Alanycarb Standard 棉铃威标准品 83130-01-2 200mg
018-17011 Allethrin Standard 烯丙菊酯标准品 584-792 200mg
019-20611 Allidocfilor Standard 二丙烯草胺标准品 93-71-0 100mg
015-09733 Alloxydim Sodium Standard 禾草灭标准品 55635-13-7 200mg
019-13641 Ametryn Standard 莠灭净标准品 834-128 200mg
011-14941 Amitraz Metabolite HydroChlonde Standard 双甲脒盐酸盐代谢物标准品 51550-40-4 200mg
015-09593 Amitraz Standard 双甲眯标准品 33089-61-1 200mg

关东化学Kanto 37047-02 二氧化硅 Silicon dioxide

关东化学Kanto 37047-02 二氧化硅 Silicon dioxide

日本关东化学代理商–上海金畔生物

代理优势:货期2-3周。

欢迎访问关东化学株式会社Kanto官网或者咨询我们获取更多产品信息。

Silica gel, Orange, middle granule

Product No. 37047-02
Package 500g
CAS RN 7631-86-9
Product instructions particle size 1.68mm~4.00mm:80%min

Harlan Teklad 2018  global 18% protein rodent diets

Harlan Teklad 2018  global 18% protein rodent diets

Harlan Teklad动物饲料
Harlan代理–上海金畔生物科技有限公司
欢迎新老客户访问Harlan官网或者咨询中国代理商上海金畔生物获取更多详细资料。

2018年全球18%蛋白质啮齿类饲料

Home + Teklad diet, bedding and enrichment + Teklad laboratory animal diets + Standard natural ingredient diets + Rodent diets + 2018 Teklad global 18% protein rodent diets

Product Features

  • Designed to support gestation, lactation, and growth
  • Formulated to reduce soybean meal, thus minimizing the presence of isoflavones, the primary type of phytoestrogen found in lab animal diets
  • Typical isoflavone concentrations (daidzein + genistein aglycone equivalents) range from 150 to 250 mg/kg
  • Exclusion of alfalfa reduces chlorophyll, greatly improving fluorescent optical imagingclarity
  • Absence of animal protein and fish meal minimizes the presence of nitrosamines (a potential carcinogen)
Products
Teklad rodent diets Non-autoclavable form Autoclavable Irradiated
Teklad global 18% protein 2018, 2018C 2018S, 2018SX 2918
Not all products are stocked locally; extended lead time and additional fees may apply.
Many diets are available in certified format designated by a “C” following the product code. When diets are certified a representative sample is tested for a panel of contaminants. If not stocked as certified, certification can be made available upon request. Minimum order size and additional charges may apply.

产品特点

  • 用于支持妊娠、哺乳和生长的
  • 减少豆粕的配方,从而尽量减少异黄酮的存在。异黄酮是大豆的主要类型。植物雌激素在实验室动物饮食中发现的
  • 典型的异黄酮浓度(大豆苷元+染料木素苷元当量)为150至250毫克/千克。
  • 紫花苜蓿的排斥降低了叶绿素含量,大大提高了叶绿素含量。荧光光学成像清晰性
  • 缺乏动物蛋白质和鱼粉可使亚硝胺(一种潜在的致癌物质)的存在减少到最低限度。
产品
特克勒德啮齿类食物 不可蒸压式 高压釜 辐照
Teklead全局18%蛋白 2018,2008 c 2008 S, 2018SX 2918
并不是所有的产品都是在当地库存的,可能需要延长交货期和额外的费用。
许多饮食都是由符合产品代码的“C”指定的认证格式提供的。当饮食被认证时,一个有代表性的样本会被测试一组污染物。如果没有经过认证的库存,可以根据要求提供认证。可适用最低订货量和附加费用。

Harlan Teklad NAFLD and NASH

Harlan Teklad NAFLD and NASH

Harlan Teklad动物饲料
Harlan代理–上海金畔生物科技有限公司
欢迎新老客户访问Harlan官网或者咨询中国代理商上海金畔生物获取更多详细资料。

Teklad diet, bedding and enrichment    Teklad laboratory animal diets   Custom research diets   NAFLD and NASH

诱导啮齿动物NAFLD/NASH的饮食方法可分为两大类:

  • 长期喂饲可诱发肥胖、代谢综合症及轻微纳什或
  • 短时间喂饲可诱发严重纳什的肝脏特征而不引起肥胖或胰岛素抵抗的饮食。

下表突出了上述两个类别的饮食选择。有关NAFLD/NASH模型的更完整描述,请参见表后面的下拉菜单。

Dietary methods to induce NAFLD/NASH in rodents can be split into two common categories:

  • diets fed for longer periods of time to induce obesity, metabolic syndrome, and mild NASH or
  • diets fed for short periods of time to induce hepatic features of severe NASH without inducing obesity or insulin resistance

This page provides further information on dietary methods to induce NAFLD/NASH. We’ve also prepared a downloadable NASH/NAFLD mini paper.

The tables below highlight diet options from both of the above categories. For more complete descriptions of NAFLD/NASH models see the drop down menus that follow the tables.

Diet options for inducing obesity, metabolic syndrome and mild NAFLD/NASH
Diet features Western/Fast Food ALIOS FPC diet
Product Code TD.88137 TD.06303 TD.160785 PWD dough

TD.190142 pellet

Fat, % Kcal 42 45 52
Fat Sources,
% by weight
21% milk fat 22% hydrogenated vegetable oil
1% soybean oil
19% hydrogenated vegetable oil
6% milk fat
4% palmitic acid
Fatty acid profile,
% total fat
66% saturated
30% monounsaturated
4% polyunsaturated
23% saturated
31% monounsaturated (cis)
12% polyunsaturated (cis)
34% trans
43% saturated
27% monounsaturated (cis)
7% polyunsaturated (cis)
23% trans
Sugars, % by weight 34.5% sucrose 22.4% sucrose 34.5% sucrose
Cholesterol, % by weight 0.2 0 1.25
Modifications TD.96121 1.25% cholesterol
TD.120528 Increased sucrose, 1.25% cholesterol
TD.120330 0.2% cholesterol
TD.130885 0.2% cholesterol, 27% sucrose
TD.140154 adds customer supplied palmitic acid

For high fat diet options to induce uncomplicated NAFLD see our Diet Induced Obesity page.

Diet options for inducing more severe hepatic NAFLD/NASH without obesity or metabolic syndrome
Diet features High Fat, Cholesterol & Cholate Methionine/choline deficient (MCD)
Product Code TD.02028 TD.90262
Fat, % Kcal 42 22
Fat Sources,
% by weight
21% milk fat 10% corn oil
Fatty acid profile,
% total fat
66% saturated
30% monounsaturated
4% polyunsaturated
14% saturated
28% monounsaturated
58% polyunsaturated
Sugars, % by weight 33.3% sucrose 46% sucrose
Cholesterol, % by weight 1.25 0
Cholate Source, % by weight 0.5 0
Related diets TD.09237 15% milk fat, 1% cholesterol
TD.88051 Hybrid version
TD.94149 MCD control diet

Diets inducing obesity, metabolic syndrome and mild NAFLD/NASH

Western or fast food style diets fed to induce NASH with metabolic syndrome contain 40 – 45% kcal from milkfat (a fat source high in palmitate) with added cholesterol (0.15 – 2%) and are high in sucrose (>30%). Dietary palmitate and cholesterol have both previously been associated with the progression from simple steatosis to NASH.

Examples:

  • TD.88137       Adjusted Calories Diet (42% from fat)
  • TD.96121       21% MF, 1.25% Chol. Diet
  • TD.120528     42% Kcal/Fat Diet (Incr. Sucrose, 1.25% Chol.)

Research use:

These diets can induce obesity, metabolic syndrome, and simple steatosis within nine weeks of feeding. Increased hepatic inflammation has been observed after 12 weeks of feeding. NASH typically requires longer feeding with fibrosis developing within nine months and late stage fibrosis including hepatic ballooning occurring after 14 – 20 months of feeding. Increasing dietary sucrose (~41%) and cholesterol (~1.25%) accelerates the NASH phenotype with steatosis, inflammation and hepatocyte ballooning observed within 12 weeks. In addition to feeding a high fat diet, providing a glucose/fructose mixture in the drinking water may further promote NASH development.

Select References:

Charlton, M., et al., Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol, 2011. 301(5): p. G825-34. http://www.ncbi.nlm.nih.gov/pubmed/21836057

Gores, G., Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A, Masuoko H. Am J Physiol Gastrointest Liver Physiol, 2015. 308: p. G159. http://ajpgi.physiology.org/content/308/2/G159

Li, Z.Z., et al., Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem, 2009. 284(9): p. 5637-44. http://www.ncbi.nlm.nih.gov/pubmed/19119140

Ioannou, G.N., et al., Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis. J Lipid Res, 2009. 54(5): p. 1326-34. http://www.ncbi.nlm.nih.gov/pubmed/23417738

Alkhouri, N., et al., Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis. J Biol Chem, 2010. 285(5): p. 3428-38. http://www.ncbi.nlm.nih.gov/pubmed/19940134

Dixon, L.J., et al., Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis. PLoS One, 2013. 8(2): p. e56100. http://www.ncbi.nlm.nih.gov/pubmed/23409132

DeLeve, L.D., et al., Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. Am J Pathol, 2008. 173(4): p. 993-1001. http://www.ncbi.nlm.nih.gov/pubmed/18772330

VanSaun, M.N., et al., High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model. Am J Pathol, 2009. 175(1): p. 355-64. http://www.ncbi.nlm.nih.gov/pubmed/19541928

Asgharpour, A., et al., A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol, 2016. 65(3): p. 579-88. http://www.ncbi.nlm.nih.gov/pubmed/27261415

Tetri, L.H., et al., Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol, 2008. 295(5): p. G987-95. http://www.ncbi.nlm.nih.gov/pubmed/18772365

Tsuchida, T., et al., A simple diet-and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. Journal of hepatology, 2018. 69(2):385-395. https://www.ncbi.nlm.nih.gov/pubmed/29572095

The American Lifestyle-Induced Obesity Syndrome (ALIOS) model involves feeding the “American fast food” diet high in trans-fats and sugar. Dietary trans-fats from hydrogenated vegetable shortening (HVO) are associated with increased insulin resistance and hepatic inflammation in rodent NASH models. In addition to diet, a glucose/fructose solution is added to the drinking water and sedentary behavior promoted by removing the overhead cage feeders in this model.

Examples:

  • TD.06303       22% HVO Diet
  • TD.120330     22% HVO + 0.2% Cholesterol Diet
  • TD.130885     ALIOS with Added Sugar

Research use:

The ALIOS model develops obesity with insulin resistance, elevated ALT levels, and steatosis within 16 weeks. Increased inflammation and early development of fibrosis have been observed at 6 months. Severe steatosis with fibrosis and inflammation develops within 12 months of feeding with 50% of the mice reportedly developing hepatic neoplasms. Adding cholesterol (0.2%) to the American Fast Food diet may accelerate NASH phenotype development.

Select References:

Koppe, S.W., et al., Trans fat feeding results in higher serum alanine aminotransferase and increased insulin resistance compared with a standard murine high-fat diet. Am J Physiol Gastrointest Liver Physiol, 2009. 297(2): p. G378-84. http://www.ncbi.nlm.nih.gov/pubmed/19541924

Tetri, L.H., et al., Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol, 2008. 295(5): p. G987-95. http://www.ncbi.nlm.nih.gov/pubmed/18772365

Mells, J.E., et al., Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol, 2012. 302(2): p. G225-35. http://www.ncbi.nlm.nih.gov/pubmed/22038829

Dowman, J.K, et al., Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. Am J Pathol, 2014. 184(5):1550-1561. https://www.ncbi.nlm.nih.gov/pubmed/24650559 

Mells, J.E., et al., Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis. J Nutr Biochem, 2014. 26(3): p. 285-92. http://www.ncbi.nlm.nih.gov/pubmed/25577467

The Fructose, Palmitate, Cholesterol and Trans-Fat (FPC) diet is a recent NASH diet that includes Western and ALIOS model diets to achieve both metabolic and hepatic NASH features within an accelerated time frame. Key features of the FPC diet include 1) a lower Met content than typical rodent diets by decreasing total protein without supplementing sulfur amino acids; 2) choline supplementation is lower than typical but is not considered deficient; 3) high in sucrose (~34% by weight); 4) 1.25% cholesterol; 5) 52% kcal from fat with fat sources including milkfat fat, palmitic acid and hydrogenated vegetable shortening to provide trans-fats. Like the ALIOS model, the FPC model also provides a glucose/fructose solution to the drinking water.

Examples:

  • TD.160785     52 kcal/Fat Diet (C16:0, HVO, AMF, Choline/Met)

Research use:

Male C57BL/6J mice fed the FPC diet and provided a glucose/fructose drinking solution developed insulin resistance and NAFLD with inflammation, hepatocyte death, and fibrosis within 16 weeks.

Select References:

Wang, X., et al., Hepatocyte TAZ/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis. Cell Metab, 2016. 24(6): p. 848-62. https://www.ncbi.nlm.nih.gov/pubmed/28068223  

Zhu, C., et al., Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Sci Transl Med, 2018. 10(468). https://www.ncbi.nlm.nih.gov/pubmed/30463916

Common diets to induce obesity (DIO) can be fed to induce uncomplicated NAFLD. These high fat diets typically contain 40–60% kcal from fat without supplemented cholesterol or cholate. Simple sugars such as sucrose or fructose can also be supplemented via diet or water to progress the fatty liver phenotype. Diets can be in pellet or powder/dough form depending on the formula. Some models require limited physical activity and in those cases diets can be fed inside the cage. For more information see our Diet Induced Obesity page.

Examples:

  • TD.08811       45%kcal Fat Diet (21% MF, 2% SBO)
  • TD.06414       Adjusted Calories Diet (60/Fat)

Research use:

In susceptible rodent models, high fat diets are commonly used to induce NAFLD with obesity and insulin resistance common metabolic features associated with NASH in humans. However, the degree of NASH pathology (steatosis, inflammation, and fibrosis) is limited or mild and varies depending on the animal model, length of feeding, and dietary components.

Diets to induce severe hepatic NAFLD/NASH without obesity or metabolic

COLLAPSE ALL TABS

Originally formulated to induce mild atherosclerosis in wild-type rodents, high fat diets containing added cholesterol (1 – 1.25%) and cholate (0.5% as sodium cholate or cholic acid) have also been useful in inducing NASH. This diet option includes purified “Western” style diets with increased cholesterol and cholate and also hybrid diets. Hybrid diets were originally developed by Beverly Paigen and colleagues by mixing a natural ingredient mouse diet in a 3:1 ratio with a concentrated purified diet (containing 5% cholesterol and 2% sodium cholate) resulting in a diet containing ~15.8% fat, 1.25% cholesterol, and 0.5% sodium cholate. Although a less refined approach, the hybrid diet is associated with increased gallstone formation and liver damage as compared to similar purified diets.

Examples:

  • TD.02028       Atherogenic Rodent Diet
  • TD.88051       Cocoa Butter Diet and Purina Mouse Chow
  • TD.09237       15% AMF Diet (1% Chol, 0.5% NaChol)

Research use:

Atherogenic diets are able to induce varied degrees of NASH with increased hepatic inflammation with early fibrosis observed after ten weeks of feeding. However, the metabolic profile typical in human NASH (obesity with insulin resistance) is not recapitulated in this model with animals typically maintaining similar body weights as control fed groups without the development of metabolic syndrome.

Select References:

Nishina, P.M., J. Verstuyft, and B. Paigen, Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res, 1990. 31(5): p. 859-69. http://www.ncbi.nlm.nih.gov/pubmed/2380634

Kamari, Y., et al., Lack of interleukin-1alpha or interleukin-1beta inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol, 2011. 55(5): p. 1086-94. http://www.ncbi.nlm.nih.gov/pubmed/21354232

Kim, D.G., et al., Non-alcoholic fatty liver disease induces signs of Alzheimer’s disease (AD) in wild-type mice and accelerates pathological signs of AD in an AD model. J Neuroinflammation, 2016. 13: p. 1. http://www.ncbi.nlm.nih.gov/pubmed/26728181

Madrigal-Perez, V.M., et al., Preclinical analysis of nonsteroidal anti-inflammatory drug usefulness for the simultaneous prevention of steatohepatitis, atherosclerosis and hyperlipidemia. Int J Clin Exp Med, 2015. 8(12): p. 22477-83. http://www.ncbi.nlm.nih.gov/pubmed/26885230

Savransky, V., et al., Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol, 2007. 293(4): p. G871-7. http://www.ncbi.nlm.nih.gov/pubmed/17690174

Methionine and choline deficient (MCD) diets are amino acid defined rodent diets deficient in methionine and choline, high in sucrose (>40% by weight) with ~10% corn oil by weight. Methionine and choline deficiency decreases fat oxidation and export of fat from the liver. Dietary sucrose is necessary for hepatic lipid accumulation and oxidation. The polyunsaturated fat in corn oil promotes hepatic lipid oxidation.

Example:

  • TD.90262       Methionine/Choline Deficient Diet

Control:

  • TD.94149       Amino Acid Control Diet

Research use:

Steatosis, increased serum alanine aminotransferase (ALT), inflammation, and hepatic fat oxidation has been observed within three weeks of feeding the MCD diet with fibrosis development after six weeks. This dietary model does not produce metabolic syndrome (an aspect of NASH in human models) and progressive weight loss (up to 40%) is associated with the MCD diet feeding.

蛋氨酸/胆碱缺乏症(MCD)日粮
蛋氨酸和胆碱缺乏(MCD)饲料是一种氨基酸定义的啮齿动物饲料,缺乏蛋氨酸和胆碱,蔗糖含量高(体重>40%),玉米油含量约10%。蛋氨酸和胆碱缺乏减少脂肪氧化和从肝脏输出脂肪。日粮蔗糖对肝脏脂质的积累和氧化是必需的。玉米油中的多不饱和脂肪促进肝脏脂质氧化。

例子:TD.90262 蛋氨酸/胆碱缺乏症饮食
管制:TD.94149 氨基酸控制饮食

研究用途:

观察到脂肪变性、血清丙氨酸转氨酶(ALT)升高、炎症和肝脂肪氧化反应。这种饮食模式不会产生代谢综合症(在人类模型中是NASH的一个方面)和累进性减肥(高达40%)与MCD饮食喂养有关。

Select References:

Pickens, M.K., et al., Dietary sucrose is essential to the development of liver injury in the MCD model of steatohepatitis. J Lipid Res, 2009. 50(10):2072-82.  http://www.ncbi.nlm.nih.gov/pubmed/19295183

Li, Z.Z., et al., Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem, 2009. 284(9): p. 5637-44. http://www.ncbi.nlm.nih.gov/pubmed/19119140

Lee, G.S., et al., Polyunsaturated fat in the methionine-choline-deficient diet influences hepatic inflammation but not hepatocellular injury. J Lipid Res, 2007. 48(8): p. 1885-96. http://www.ncbi.nlm.nih.gov/pubmed/17526933

Vetelainen, R., A. van Vliet, and T.M. van Gulik, Essential pathogenic and metabolic differences in steatosis induced by choline or methione-choline deficient diets in a rat model. J Gastroenterol Hepatol, 2007. 22(9): p. 1526-33. http://www.ncbi.nlm.nih.gov/pubmed/17716355

Leclercq, I.A., et al., Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone. Lab Invest, 2007. 87(1): p. 56-65. http://www.ncbi.nlm.nih.gov/pubmed/17075577

Kashireddy, P.R. and M.S. Rao, Sex differences in choline-deficient diet-induced steatohepatitis in mice. Exp Biol Med (Maywood), 2004. 229(2): p. 158-62. http://www.ncbi.nlm.nih.gov/pubmed/14734794

Dixon, L.J., et al., Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab Invest, 2012. 92(5): p. 713-23. http://www.ncbi.nlm.nih.gov/pubmed/22411067

Dietary models of NAFLD/NASH continue to evolve with the goal of more accurately recapitulating both the metabolic and hepatic symptoms of human disease. Commonly researchers are studying the synergistic effects of various NASH dietary features to accelerate progression of the model and severity of liver disease.

A Teklad nutritionist can work with you to formulate new diets in order to investigate novel dietary models of NAFLD/NASH.

The choice of control diet is dependent on the specific research goal. Many researchers choose to compare their NAFLD/NASH diet-fed animals to animals fed a natural ingredient, grain-based diet (also referred to as standard diet or chow). These diets differ in the source and level of nutrients as well as in the presence of non-nutritive factors (such as phytates or phytoestrogens).

Depending on what your main comparisons are, it may be suitable to have a grain-based diet as your control/reference group. However, making such comparisons limits inferences to dietary patterns versus a specific dietary component. In some cases, such as those studies feeding amino acid defined diets like the MCD model, a matched control diet is recommended given the very different formulations and protein sources of grain-based diets.

When making inferences about specific nutrients within the diet an ingredient matched, low fat control diet may be necessary. There are many options with different levels and types of fat in addition to different types of carbohydrate ranging from sucrose (highly refined and digestible) to corn starch (refined, but more complex) to resistant starch (refined, but not fully digestible).

A very basic purified control diet would be AIN-93M TD.94048 or AIN-93G TD.94045. AIN-93 diets have a moderate amount of sucrose at ~10% with fat from soybean oil providing a healthy fatty acid profile.

Contact a nutritionist for an additional information and control diet recommendations.

对照日粮
控制饮食的选择取决于具体的研究目标。许多研究人员选择比较他们的NAFLD/纳什饮食喂养的动物和喂养一种天然成分的动物,谷物为基础的饮食(也称为标准饮食或周食)。这些饮食在营养来源和水平以及非营养因素(如植酸盐或植物雌激素)存在的情况下存在差异。

根据您的主要比较,它可能适合作为您的对照/参考组谷物基础的饮食。然而,这样的比较限制了对饮食模式和特定饮食成分的推断。在某些情况下,如那些研究喂食氨基酸定义的饮食,如mcd模型,建议一个匹配的对照饮食,考虑到非常不同的配方和蛋白质来源的谷物为基础的饮食。

当对饮食中的特定营养成分做出相应的推断时,低脂控制饮食可能是必要的。除了不同类型的碳水化合物外,还有许多不同水平和类型的脂肪,从蔗糖(高精制和可消化)到玉米淀粉(精制,但更复杂),再到抗性淀粉(精制,但不能完全消化)。

一种非常基本的纯正控制饮食将是-9300万。TD.94048或者是93g TD.94045。AIN-93日粮中含有适量的蔗糖~10%,大豆油中的脂肪提供了健康的脂肪酸谱。

Need more information? A Teklad nutritionist will work with you to determine if existing diets will meet your needs or formulate new diets to help you investigate novel dietary models of NAFLD/NASH. Contact us for a diet consultation.

Harlan TD.07864 1% Choline Diet (2018)饲料说明书

Harlan TD.07864 1% Choline Diet (2018)饲料说明书

Harlan Teklad动物饲料
Harlan代理–上海金畔生物科技有限公司
欢迎新老客户访问Harlan官网或者咨询中国代理商上海金畔生物获取更多详细资料。

Formula g/Kg
2018, Teklad Global 18% Protein Rodent Diet 988.2
Choline Chloride, customer supplied 11.8

Footnote

The 2018 Teklad Global diet with 1% added choline from choline chloride (approx. 85% choline).

Selected Nutrient Information1

  % by weight % kcal from
Protein 18.0 22.9
Carbohydrate2 47.4 60.5
Fat 5.8 16.6
Kcal/g 3.1  
  • Values are calculated from ingredient analysis or manufacturer data
  • Estimated digestible carbohydrate

Key Features

  • Standard Diet Base
  • Choline
  • Customer Supplied Ingredient
  • Teklad 2018

Key Planning Information

  • Products are made fresh to order
  • Store product at 4°C or lower
  • Use within 6 months (applicable to most diets)
  • Box labeled with product name, manufacturing date, and lot number
  • Replace diet at minimum once per week

More frequent replacement may be advised

  • Lead time:
  • 2 weeks non-irradiated
  • 4 weeks irradiated